Lactulose

Generic Name: Lactulose

Brand Names: Constulose, Enulose, Generlac, Kristalose

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₂O_₁₁

CAS Number: 4618-18-2

Unique Ingredient Identifier: 9XH2P2N8EP

Background: Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE). Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipa...

Indication: Lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patients.
...

Associated Conditions: Constipation, Hepatic Encephalopathy (HE)

Associated Therapies: -

Clinical Trials

S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE

Not Applicable

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: Lactulose
Drug: placebo

First Posted Date: 2011-10-05

Last Posted Date: 2012-04-10

Lead Sponsor: Govind Ballabh Pant Hospital

Target Recruit Count: 60

Registration Number: NCT01446523

Locations: 🇮🇳
BC Sharma, New Delhi, Delhi, India

Pilot Study of the Effect of Lactulose on Post Caesarean Section Constipation

Not Applicable

Conditions: Constipation
Abdominal Pain
Nausea
Vomiting

Interventions: Drug: Lactulose

First Posted Date: 2011-02-14

Last Posted Date: 2011-02-23

Lead Sponsor: NHS Fife

Target Recruit Count: 30

Registration Number: NCT01295138

Locations: 🇬🇧
Forth Park Hospital, Kirkcaldy, Fife, United Kingdom

Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.

Not Applicable

Completed

Conditions: Portosystemic Encephalopathy
PSE
Hepatic Encephalopathy
Cirrhosis

Interventions: Drug: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)
Drug: Lactulose

First Posted Date: 2011-01-25

Last Posted Date: 2014-12-11

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 50

Registration Number: NCT01283152

Locations: 🇺🇸
University of Texas Southwestern Medical Center and Parkland Memorial Health and Hospital System, Dallas, Texas, United States

Kristalose as Bowel Evacuant Prior to Colonoscopy

Phase 1

Completed

Conditions: Bowel Evacuant Prior to Colonoscopy

Interventions: Drug: Kristalose

First Posted Date: 2010-12-08

Last Posted Date: 2011-10-06

Lead Sponsor: Benaroya Research Institute

Target Recruit Count: 20

Registration Number: NCT01256541

Locations: 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.

Not Applicable

Completed

Conditions: Cirrhosis

Interventions: Drug: L-carnitine
Drug: Lactulose

First Posted Date: 2010-11-01

Last Posted Date: 2013-02-27

Lead Sponsor: University Hospital, Caen

Target Recruit Count: 55

Registration Number: NCT01231828

Locations: 🇫🇷
University Hospital of Caen, Caen, France

Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

Not Applicable

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: Rifaximin plus lactulose
Drug: Lactulose

First Posted Date: 2010-10-11

Last Posted Date: 2013-04-04

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 120

Registration Number: NCT01218568

Locations: 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis

Phase 4

Conditions: Hepatic Encephalopathy

Interventions: Drug: Probiotics(VSL#3)
Drug: Lactulose

First Posted Date: 2010-08-10

Last Posted Date: 2010-08-10

Lead Sponsor: Govind Ballabh Pant Hospital

Registration Number: NCT01178372

Locations: 🇮🇳
G B Pant Hospital, New Delhi, Delhi, India

Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis

Phase 4

Conditions: Hepatic Encephalopathy

Interventions: Drug: Lactulose

First Posted Date: 2010-08-05

Last Posted Date: 2010-08-05

Lead Sponsor: Govind Ballabh Pant Hospital

Registration Number: NCT01175538

Locations: 🇮🇳
G B Pant Hospital, New Delhi, Delhi, India

Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life

Phase 2

Completed

Conditions: Chronic Liver Disease
Hepatic Encephalopathy

Interventions: Drug: VSL#3
Drug: Lactulose

First Posted Date: 2009-11-05

Last Posted Date: 2013-06-04

Lead Sponsor: CD Pharma India Pvt. Ltd.

Target Recruit Count: 120

Registration Number: NCT01008293

Locations: 🇮🇳
Dept. of Gastroenterology and H.N.U., All India Institute of Medical Sciences, New Delhi, Delhi, India

A Study of Controlled Lactulose Withdrawal

Not Applicable

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: lactulose

First Posted Date: 2009-06-04

Last Posted Date: 2013-03-20

Lead Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center

Target Recruit Count: 7

Registration Number: NCT00914056

Locations: 🇺🇸
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy